Why Target APRIL in IgA Nephropathy Management? Get Up to Speed With the Mechanisms of Action and Key Data

Explore emerging B-cell-targeted therapies for immunoglobulin A nephropathy (IgAN). Unpack novel mechanisms of action (MOAs) and the latest clinical data to protect kidneys now.

Credit available for this activity expires: 8/5/27
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/why-target-april-iga-nephropathy-management-get-speed-2026a1000ooh?ecd=bdc_podcast_libsyn_mscpedu